 LEXINGTON, Mass.--BUSINESS WIRE--Aldeyra Therapeutics, Inc. Nasdaq: ALDX Aldeyra today announced it will host a webcast and conference call on Wednesday, June 8, 2022, at 8:00 a.m. ET to provide top-line results from the Phase 3 TRANQUILITY-2 Trial of reproxalap in dry eye disease. The dial-in numbers are 844 200-6205 for domestic callers and 929 526-1599 for international callers. The access code is 879247. A live audio webcast of the conference call also will be accessible from th 